Julia Hughes, MD
Gastroenterology · Raleigh, NCNPI 1982996385
Payments from drug & device makers
Across 366 payments — averaging $31.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- AbbVie$2K
- Bristol Myers Squibb$870
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$667
- Johnson & Johnson$499
- Pfizer$402
- plus $3K from 30 others
What the payments were for
- Consulting fees$4,63841%
- Travel & lodging$7697%
- Food & beverage$5,60249%
- Education$2452%
- Gifts$1962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $4,638 |
| AbbVie(2 entities) | 130 | $1,671 |
| Bristol Myers Squibb | 16 | $870 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $667 |
| Johnson & Johnson | 21 | $499 |
| Pfizer | 29 | $402 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $366 |
| Regeneron Healthcare Solutions, Inc. | 10 | $223 |
| Celltrion USA Inc. | 11 | $222 |
| Braintree Laboratories, Inc. | 7 | $196 |
| Biotronik NRO, Inc. | 2 | $184 |
| QOL Medical, LLC | 11 | $178 |
| Lilly USA, LLC | 10 | $173 |
| Ardelyx, Inc. | 9 | $170 |
| Phathom Pharmaceuticals, Inc. | 8 | $141 |
| Novo Nordisk | 9 | $137 |
| Abbott | 4 | $94 |
| Aimmune Therapeutics, Inc. | 4 | $90 |
| Gilead | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $61 |
| Boehringer Ingelheim | 3 | $53 |
| Merck | 3 | $50 |
| Amgen | 3 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Intercept Pharmaceuticals, Inc. | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Sanofi | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Shionogi Inc | 1 | $18 |
| Vivus LLC | 1 | $16 |
| Capsovision, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Echosens North America, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,450 in reported general payments places this provider in the 75th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 13 | $373,219 |
| Humira(Cf) PenAdalimumab | 45 | $346,066 |
| CreonLipase/Protease/Amylase | 19 | $47,133 |
| LinzessLinaclotide | 51 | $42,326 |
| XifaxanRifaximin | 13 | $34,942 |
| TrulancePlecanatide | 44 | $29,110 |
| Mesalamine ErMesalamine | 44 | $25,393 |
| Mesalamine | 34 | $19,565 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 57 | $9,158 |
| Dexlansoprazole DrDexlansoprazole | 19 | $7,991 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 104 | $7,424 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 30 | $5,095 |
| Ursodiol | 18 | $4,919 |
| Omeprazole | 171 | $3,043 |
| Sucralfate | 36 | $2,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $499 | $373,21913 claims |
| AbbVieCreon, Linzess | $1,671 | $89,45970 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $667 | $64,05257 claims |
| Braintree Laboratories, Inc.Sutab | $196 | $9,15857 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $31 | $5,09530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Raleigh
- Angela HiraRaleigh$513K
- Charles BarishRaleigh$185K
- Evan DellonChapel Hill$11.2M
- Andrew MuirDurham$6.6M
- Manal AbdelmalekDurham$5.6M
- Robert ReindollarSalisbury$2.5M
- John PoulosFayetteville$2.1M
- Hans HerfarthChapel Hill$2M
- Herbert BonkovskyWinston Salem$1.7M
- Ikechukwu IbegbuJacksonville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.